U.S. Markets closed

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.15-2.19 (-17.79%)
At close: 4:00PM EDT
Sign in to post a message.
  • A
    Ariadinvestor
    M/Jt: "1. Ariadinvestor, being invested in AUPH and SRNE, you lost all the profit from Ariad windfall. Shame on you for not cutting your losses; 2. SRNE will be the first to $0; 3. Ariadinvestor getting absolutely destroyed." @M/Jt 😁 Didn't you say "Ariadinvestor has never owned any stocks"? 🤣 How could I get destroyed with $SRNE given I added 10,000 shares @ 1.57/1.52 on 11/18/19 & took some profits @ 10/18.82 on 2020-05-18/2020-08-10? I'm going to post the Links To M's posts:
    Bullish
  • A
    Ariadinvestor
    @Jt/M ? "Didn't you say ARIA would drop to $2 & bankrupt right before the $24 buyout? History repeats itself. Both you & I are repeating the Ariad war. I won it as Ariad’s science & pipeline eventually won. I will also win the $AUPH / $SRNE wars as time will let you know it. Will you declare defeating me again by abusing your Yahoo Admin power & deleting my posts/accounts? You’ve left tons of evidences for Verizon to get sued. You don't care about losing your 1st job as a Yahoo Admin because you get paid more from your 2nd job as a paid basher, right? " I've been posting this since 07/05/2019.
    Bullish
  • A
    Ariadinvestor
    @John 😁 On Oct. 11, 2013, ARIA was down 80%. So what? AUPH was down only 22% after hours. So what? Tomorrow is another day. Next week is another week. Next month is another month. Next year is another year. Next decade is another decade. God bless LN patients! God bless $AUPH . God bless $SRNE ! Short squeeze is just a matter of time. ARIA did drop 80% on 10/11/2013. Short squeeze did happen on 01/07/2017 when Ariad was bought out. Louis XIII !
    Bullish
  • A
    Ariadinvestor
    John: "Where is Ariadinvestor?" My enemy M/Jt always asked the same question whenever ARIA was down. He cheered • Oct 11, 2013 11:04 PM: "HAHAHAHAH I'm so happy I could cream! WHERE IS ariadinvester? HAHAHAHA" I replied: "My paper gain is still over 580% for the share I bought at 0.625, and 425% for the share I bought at 0.81. You are truly a lowlife. "

    AUPH down only 22% after hours. So what? On Oct. 11, 2013, ARIA was down 80%. So what?

    During my 18.5 years of accumulating ARIA gold bags, I saw ARIA's low of 0.50 & its high of 48.50. AUPH/SRNE gold bags will be proven bigger than ARIA. Time will let Jt/M and John know it. I still held my ARIA shares bought @ 0.80 when ARIA was bought out @ 24. No bags no gold. This is to respond to Yahoo Admin M/Jt who posted: "Markets will be RED, ARIANDInvestor will molest a goat tonight and thus stock will be stagnant until May" Link: https://finance.yahoo.com/quote/AUPH/community?p=AUPH&messageId=ef99c4a4-ee99-4cf6-a9fc-795e0f800723 @Jt/M 😁 If you are a man, please don't delete this. So that we can have a fair discussion. But I am afraid that you are not a man. Obviously, you've shorted $AUPH at the new bottom price. Long live $SRNE short squeeze !

    "The 75,107,937 shares shorted are the best friends of the true longs. Sooner or later, THE SHORTS WILL BE FORCED TO COVER," I posted on 09/28/20. * SRNE CEO Ji: "My goal is to build Sorrento into a $200 billion company in the next 3 to 5 years." AUPH, Gold Bags; SRNE, Bigger Gold Bags. I don't set stop loss. I don't buy on margin. I don't sell but add more when it pulls back. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me. God bless $SRNE / $AUPH investors. I really mean what I'm saying.

    This is to respond to John who wrote: "where is that araid moron lol he has to be broke by now he probably contemplating which bridge to jump off of"

    Link: https://finance.yahoo.com/quote/AUPH/community?messageId=48e5d4a1-6aaf-4dcf-85de-9a7e5f5342f9&bcmt=1

    === Junk below this line ===

    https://insiderfinancial.com/sorrento-stock-the-mayo-clinic-news-is-a-big-deal/180416/?fbclid=IwAR0Yt2PGw-p6Pr7P_tjc_bI7dS1RG8OoGcDx-Blx1q9LrP9pyXdMeP4Qfr
    No announcement yet on Q4 earnings call, but based on last year it will be early March. Probably want to hold stock at least until then as we'll likely get guidance/forecast of 2021 sales and margins (and perhaps hints on BO status).
    I think the 2021 full year guidance/foreacst will be surpringly robust based on the Jan 25th call where management emphasized "Commercial Launch Uniquely Prepared for Success" by highlighting:
    - Fully staffed Commercial Team with extensive Rheumatology and Nephrology experience
    - Identified ~12k physician targets
    - Completed physician profiling of highest SLE prescribers
    - Delivered Speaker/Disease Awareness programs reaching more than 1,000 HCPs
    - Launched first Lupus Nephritis pharma-sponsored consumer disease state awareness (DSA)
    program with over 140K impressions
    - Engaged HCPs in Academic Centers with DSA campaign notwithstanding COVID-related restrictions
    - Executed pre-approval information exchange with more than 50 payers covering two-thirds of
    commercially insured lives.Aurinia has more than $400M in cash; well capitalized for successful launch
    - Product available for prescribing
    - Patient Support Program Aurinia Alliance online with dedicated nurse case managers and reimbursement
    support
    - Targeting Nephrologists & Rheumatologists with active LN patients
    - Launching in-person and virtual branded campaign
    - Ensure patient education regionally through advocacy and HCP engagement
    - Potential peak annual U.S. net sales of greater than $1 billion
    Less

    Sponsored Post:
    Aurinia Pharmaceuticals announced that the US Food and Drug Administration has approved its Lupkynis treatment for use in adult patients with active lupus nephritis, an autoimmune kidney disease. Check disclaimer on the landing page. Apart from it, these other industries could disrupt this potentially $1.08 trillion market. Is it really nice to know about this trends? Have a break to check this one: https://prem.li/MustSee-ElectricVehicles-Market
    Bullish
  • A
    Ariadinvestor
    $SRNE conversation
    This is also to madden my enemy Yahoo Admin M/Jt => I started to accumulate AUPH early 2017 when it was at @2.90. I posted on 2017-11-22: "I added 7,001 shares @4.68-5.28 on 11/15/2017; 2000 shrs @5.48 11/14/17; 2000 shrs @5.66 10/26/17; 2000 shrs @5.76 10/24/17; 2000 shrs @5.98 10/23/17; 2000 shrs @6.13 10/20/17; ... 4,000 shrs @5.90 around 8/8/17; & I added ..." * Unlike the shorts/bashers who are liars, I actually do what I say. I was accused of pumping $AUPH when Yahoo Admin M shorted it at $3.52 on 10/10/2019. I don't sell but add more when it pulls back.
    Bullish
  • K
    K Smooth
    I just listened to PG and MC on the conference call again (first 15 minutes). If I wasn't already completely loaded I would add at these levels. I would not listen to Imbeciles like @Confucious or the other trolls. Listen to the CC again without the background of the insane market reaction and make your own assessments. Man I wish I had not dipped into margin already .. I still have a cushion for it to go down further but I can't take on any additional risk.

    I would suggest everyone just hold tight .. it may take longer than expected. A year from now I think any stockholder will be thrilled with the return whether you bought at $10 or even $20.
  • A
    Ariadinvestor
    $SRNE conversation
    To WildBill, Dennis, Jerry / whoever accuses me of being a short: Let's swear to God I would burn in hell if I was a short, or your whole clan will burn in hell. I still own far more shares than a Justin, who said he owned far more shares & asked me to leave, although I took some profits @ $10 & $18.82 on 05/18/20 & 08/10/20 "to take out cost basis & free roll it" in K Smooth's words.

    Responding to false accusations, I either swear to God or ask the accuser to swear to God in order to set the record straight. @Jerry/WildBill/Dennis ✔ Dare you swear to God that your accusers' whole clans will burn in hell after dying the most painful deaths if I've never shorted any biotech stocks? I swear to God that I own $AUPH / $SRNE & I added 10,000 SRNE shares @ 1.52/1.57 on 11/18/2019. Long live short squeeze !

    https://stocktalkforums.com/forums/topic/26-reasons-to-love-sorrento/

    https://www.nasdaq.com/articles/sorrento-therapeutics-stock-could-more-than-double-says-analyst-2021-01-30

    God bless $AUPH / $SRNE investors.

    == The followng is junk:==
    "
    Interesting line in this quotation: "reasonably assured..."

    "R&D expenses decreased to $4.8 million for the third quarter ended September 30, 2020 compared to $17.8 million for the same period in 2019. The decrease is due to a decrease in activities related to clinical trials and exploratory development work and the capitalization of inventory and internal development costs as management believes that approval by the FDA of voclosporin as a treatment for LN was reasonably assured."

    the Bullish Report on Sorrento Therapeutics, Inc.

    https://chart-analysis.tools/SRNE

    Top Gainers in the U.S. Stock Markets 🇺🇸

    https://stockreport.tips/Top-Market-Gainers

    The market expects Sorrento Therapeutics (SRNE - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2020. If you want investment ideas from real knowledgeable traders, check them out at the https://investena.today/recommends/exclusive-stock-trading-masterclass/ platform

    "
    Topic: 26 Reasons to Love Sorrento | Stock Talk Forums
    stocktalkforums.com
    Bullish
  • A
    Ariadinvestor
    CPRX-ATRS (JJ82): "...Dany - James/Fred/Eric/Roberta2 & Cristina/Sara ... : You claim that Ariad is annoying because of his repeating stories and gifs. Do you want to know what I think of him???? This guy and his amazing story of Ariad brought me to put Sorrento to my watchlist. I started analyzing this company and the evaluations were amazing. Why the hell increased their share price from 2 to 10$ within ust a few month??? What you you think, is it just a garbage stock??? I dont think so, I guess peoaple thought it would happen immediatley but thy were wrong, for sure. Celgene did not grow to an outstanding company within 1 or 2 years, its a long period of development. Not to invest in such a company which just has outstanding evaluations and probably can heal pancreatic cancer in the future is idiotic and very risky to me. I would never put whole of my money into but at least 20% of my portfolio. If the story continues successful you will be very angry, I am sure."

    Link: https://finance.yahoo.com/quote/SRNE/community?messageId=8fba649b-5a2d-4b7d-9ab7-d069f3f9c302&replyId=136534dd-6fe0-4366-b37b-951f41241321

    @CPRX-ATRS * Please comment on your own post. 🤣

    * AUPH shares are still gold bags. $AUPH / $SRNE short squeeze is just a matter of time.
    Bullish
  • C
    CPRX-ATRS
    What is wrong with this board and SRNE? Everything just because of Ariadinvestor. 50, 100 30 TU or TD??? I think I need to mute a lot of eople here to read some useful posts. Just started tu buy AUPH, maybe SRNE as well next time.
  • C
    Chip
    Clearly AUPH's report was disappointing and the market did not like the news, but I do not believe it qualifies as a disaster. Why? AUPH had less than two months to sell its first product, which is not a lot of time for market penetration especially when dealing with the challenges of the pandemic.

    Meanwhile, Oncternal Therapeutics (ONCT) announced today after hours an EPS miss by $0.02, it missed on revenue, and its stock is up +1.83% after hours.

    Regarding AUPH, in a press release the company said its cash and cash equivalents, and investments were $422.7 million as of December 31, 2021. As of March 31, 2021 cash and cash equivalents was $360.9 million. The decrease was primarily related to the commercial infrastructure spend to support the launch of LUPKYNIS, an upfront payment made as part of a collaborative agreement with Lonza to build a dedicated manufacturing facility, and one-time payment to a related party upon achievement of specific milestones.

    The company said, "(It) believes that it has sufficient financial resources to fund its current plans," which hopefully prevents a secondary offering. I believe the company has about two years of cash on hand before it needs to sell the business, sell more product, or do a secondary offering. I believe it should be o.k. and not need to raise cash, if my revenue projections are accurate, if the company remains an independent business enterprise.

    I listened to AUPH's conference call and I am going to listen to it again to get clarity. Some of the points management made and then I will discuss my thoughts.

    1. LUPKYNIS prescriptions were depressed in COVID hot spots such as NY, MA, and MI. LUPKYNIS prescriptions were robust in pandemic open states like like FL and TX. Management said, "We did not expect COVID to have such an impact” and "the (ramp up) trend will evolve and increase as the country opens up."

    2. There are about 60 Lupus treatment clinics in the U.S. 50% of the treatment centers are still down (closed) due to COVID-19 and the other clinics are seeing patients remote.

    3. The company believes LUPKYNIS market penetration will improve as the pandemic subsides.

    4. Management believes the numbers were "in line with our expectations” and it "feels good about the trends it is seeing."

    5. Management is encouraged by the feedback they receiving from doctors and patients.

    6. 11 major insurance companies cover LUPKYNIS as a specific policy benefit. There is nothing that stands out as a patient prescription denial as seen as in other new drug launches.

    Every analyst who asked a question congratulated management on the LUPKYNIS(TM) start up. I have listened to hundreds of airline conference calls in the past where there was some clear doom and gloom after the two Gulf Wars, the energy crisis, 911, COVID-19 break out, etc. The airline conference calls always had me concerned, but tonight's seemed upbeat and positive by both management and the analysts for a miss, which I found surprising.

    Remora would know better than me, but AUPH had over 250 patient patient start forms received in about 2 months (48 business days). If you extrapolate that and add 10 more months that would be an additional 1,250 patients this year or 1,500 patients in year one, which would project about $97.5 million in annualized revenue ($65,000/year for the drug times 1,500 patients). This excludes insurance coverage and no growth in uptake, which is probably unlikely.

    It will be interesting to see the analyst target stock price when their research reports are released. With the company's stock price slightly above $10 per share the premium paid by an acquiring company would be lower than before.

    With 50% of the Lupus treatment centers closed and other centers seeing patients via Zoom, I wonder if the forecast for market penetration growth and a lower acquisition price might increase the odds of a merger? I think so...

    Obviously, this assumes an acquiring company's executive team feels optimistic about AUPH's prospects for long-term earnings growth as I described above.

    A friend of mine said, "I think AUPH will do well longer term and will get bought at some point but it is going to be a wait. They basically had 40 days to begin sales this quarter and like everything else it takes time to deal with insurance and to educate doctors. Analysts were unduly optimistic. It is going to be dead money for a while, but if it gets under $10 again I'd likely buy."

    I agree.
    Bullish
  • A
    Ariadinvestor
    @Jt/Fred 😊 A falling knife is sweet. I would catch the AUPH/SRNE falling knives now if my portfolio was not heavily weighted in the 2 stocks. I caught the NK/NIO falling knives @ 1.15/1.99 on 2019-11-08. Sweet! I added 10,000 the SRNE falling knives @ 1.57/1.52 on 2019-11-18. Sweet! I caught the ARIA falling knives @ 0.625/0.80 in 1999-10/2018-12. Sweet! Sweet! ... I don't sell but add more when it pulls back. I don't set stop loss. I don't buy on margin. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me. I really mean what I'm saying. God bless $SRNE / $AUPH investors. Short squeeze is just a matter of time.
  • A
    Ariadinvestor
    1. Shirts vs Blouses: "Ariadinvestor is a treasure to this board. He does the much needed dirty work for true longs."
    2. Jack replied: "He is a voice of intelligence and sanity, all psychos hate that."
    3. Me: "Only true longs appreciate what I do here. Thanks, Shirts vs Blouses and Jack!" 👌 I swear to God they are not me.

    Shirts vs Blouses's post was deleted a week later by my enemy Yahoo Admin M/Jt.

    It took Alex Denner 3.3 years to get the right buyer of Ariad at the right price. Crybabies, why should PG sell Aurinia right away simply because you're way worried about your position or you're afraid that it may go back around $6? Please capitulate now! Thx! There'll be no buyout before you capitulate. So please do the true long a favor & sell now. ✔ Patience is the key to the ultimate success of a true long's investment. I don't sell but add more when it pulls back. I don't set stop loss. I don't buy on margin. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me. God bless $SRNE / $AUPH investors. I really mean what I'm saying.

    @Jt/Fred 😊 A falling knife is sweet. I would catch the AUPH/SRNE falling knives now if my portfolio was not heavily weighted in the 2 stocks. I caught the NK/NIO falling knives @ 1.15/1.99 on 2019-11-08. Sweet! I added 10,000 the SRNE falling knives @ 1.57/1.52 on 2019-11-18. Sweet! I caught the ARIA falling knives @ 0.625/0.80 in 1999-10/2018-12. Sweet! Sweet! ... I don't sell but add more when it pulls back. I don't set stop loss. I don't buy on margin. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me. I really mean what I'm saying. God bless $SRNE / $AUPH investors. Short squeeze is just a matter of time.

    I don't sell but add more when it pulls back. I don't set stop loss. I don't buy on margin. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me. God bless $SRNE / $AUPH investors. I really mean what I'm saying.

    This is how I invest in biotech: 4. LAST BUT NOT LEAST, enjoy my hobby/online-entertainment of taunting/striking back provocateurs; 3. Take it easy at bad times; 2. Have patience; 1. Pick up the right gold bag stocks. I REALLY MEAN WHAT I'M SAYING. AUPH/SRNE's great science & pipeline will shine. Patience is the key to the ultimate success of the investors. Before Ariad was bought out, I had been accumulating its shares for 18.5 years with my belief that its great science & pipeline would shine. Time will let my haters know $SRNE / $AUPH are even big gold bags than $ARIA gold bags. Cheers!
    Bullish
  • C
    Chip
    Aurinia Pharmaceuticals (AUPH -18.2%) has plunged after the company’s Q1 financials came below expectations.

    Weighing on the results, Cantor Fitzgerald has maintained the overweight rating and the price target of $34.00 per share which indicates an upside of ~175.5% to the last close.

    With two months into the launch amid COVID impact, the company "is off to a good start" in terms of LUPKYNIS sales, the analyst Alethia Young argues citing positive patient start form trends.

    Even though the failure to meet the consensus has weighed on the stock, "the real focus is future trends" the analyst wrote pointing to new scripts, payer coverage, and feedback from physicians all of which seemed positive on the earnings call.

    The company has ended Q1 with 257 patients start forms and a solid yet early conversion rate, Peter Greenleaf CEO of Aurinia noted on the earnings call, adding “these trends continue and have grown into the early part of Q2.”
  • C
    Confucius
    10Q:

    "We are devoting the majority of our operational efforts and financial resources towards the
    commercialization and post approval commitments of our approved drug, LUPKYNIS. Taking into consideration the cash and cash equivalents and short term investments balance as of March 31, 2021, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, including our FDA related post approval commitments, manufacturing commercial drug supply, conducting our planned R&D programs and funding our supporting corporate and working capital for at least the next 12 months."

    Then Joe Miller says we are good to go to at least into 2023.

    so which one is it? next 12 month or into 2023.
  • A
    Anonymous
    My letter on April 19th

    Kind attn: Dr. Peter Greenleaf, CEO

    Dear Sir,

    Greetings.

    Every CEO and the Board were very flamboyant and provided rosy pictures along with ambitious targets only to prop up the share price, encashed their options and left the shareholders in lurch.

    Orexigen having best of the breed weight loss drug with a $4 bln market cap at peak - went to zero and even the debt holders didn’t get 30 cents on the $.

    Affymax - had  over $30 a share at the peak went to zero after blocked by FDA when an adverse event occurred, filed for Bankruptcy shareholders couldn’t even recoup 5 cents.

    Acheogen - best of breed new generation anti-biotics drug had over $2 bln market cap went belly up shareholders couldn’t receive 1 cent.

    All these had just 1 Drug, hyped way too much , the Board, Senior management exited opportunistically and left the shareholders in lurch by not selling the company when they had opportunity to sell itself.

    One drug wonder companies which went into marketing on its own took way long, burnt too much money and most of them failed miserably  only to see their share price decimate and diluted numerous times and the shareholders lost their life savings with the Management’s experiment.

    This company should sell itself to a bigger pharma and the shareholders will be better served to be part of the larger organization with multiple product portfolio rather than risking their investments with a single product company. Given the current $12 share price any offer higher than this price should be entertained by the BOD towards a competitive bidding process.

    Thanking you,

    Gl!
  • I
    I strike back 100 times
    $SRNE conversation
    @Viva Zapata! 😁 Fortunately, you were driven off this MB by Ariadinvestor. You're not bothered by him anymore. Congratulations! 😁 If you were not a shameful fool, you would not come back given you've declared your being driven off. So you've eaten your words. Even the shorts are less shameless than you. You are as shameless as Dennis & Mark on AUPH MB. 😂

    The following was posted by Ariadinvestor:

    "The 75,107,937 shares shorted are the best friends of the true longs. Sooner or later, THE SHORTS WILL BE FORCED TO COVER," I posted on 09/28/20. * SRNE CEO Ji: "My goal is to build Sorrento into a $200 billion company in the next 3 to 5 years." AUPH, Gold Bags; SRNE, Bigger Gold Bags. I don't set stop loss. I don't buy on margin. I don't sell but add more when it pulls back. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me. God bless $SRNE / $AUPH investors. I really mean what I'm saying.

    https://insiderfinancial.com/sorrento-stock-the-mayo-clinic-news-is-a-big-deal/180416/?fbclid=IwAR0Yt2PGw-p6Pr7P_tjc_bI7dS1RG8OoGcDx-Blx1q9LrP9pyXdMeP4Qfr

    Link to Ji's presentation at Riley Oncology Virtual Conference:
    https://www.webcaster4.com/Player/Index?webcastId=39569&g=e319a007-37e0-4ca7-99c2-592072e1500d
    Transcripts:
    https://seekingalpha.com/article/4400090-sorrento-therapeutics-inc-srne-ceo-henry-ji-presents-b-riley-virtual-oncology-conference

    " ...
    Mayank Mamtani

    Okay. I do want to spend some time summarizing all this in terms of what one should what an investor should think about from a data generation standpoint. And maybe just focusing on cancer. We can also touch on the timelines for COVID. But before we go there I have to end the final leg with another platform that you have from the Mayo Clinic, which is ADNIC, right. It's the next generation ADC. So could you just briefly talk about that and then we can go into sort of how your 2021 looks like?

    Henry Ji

    Yes. So as a strategic position all big pharma all biopharma company is all about the combination. Now they have to pull different drugs from different company and putting them together. For example you need a cell therapy pull one from one company and you want the Immune checkpoint PD1, PDL1, you need to go to Merck or you need Roche for PDL1 antibody there you need you know our 15 stuff like this. This different places putting together the combo. The beauty of a Mayo Clinic Technology would call the antibody drug nanoparticle albumin-bound or ADNAB complex immunocomplex. There can be one complex including all of the combination. For example you have a chemo compound paclitaxel. And GOF with ABRAXANE, which is a multibillion dollar drug from Bristol by Celgene and you have the ADNAB and that you're putting antibody on it. The beauty of that to stabilize the complex. They were not just integrated in the bloodstream. So very limited that go to a normal tissue and you have antibody on it. It will go to the -- it was 116 nanometer. They go to only the cancer side, which has a leakage, everything else normal tissue they're not getting because you need below the 60 nanometer.

    Now, with antibody you can have a targeting effect right, for example, the RITUXAN you're targeting CD20. Now the beauty you can put in anti-angiogenesis on it, for example, you can put Avastin on it. So it's an anti-angiogenesis. If you're putting the PDL1 on it, you're not only targeting the solid tumors, which they express the PDL1, you also have a immuno checkpoint the activity that to re-germinate the T cell. Now, if you even further we have innovation, if you put a cytokines on top of that, you can stimulate the T-cell. Now if you have a Hal2 it's only stimulate the T effective cells not stimulate the T-reg. You can have multiple of modality on it. Imagine you can put even the ADC on it. So, for example, you can put a CD38 ADC onto that. Then you have two chemo. One is chemo, one is toxin. Two mechanism of action. Then you have a targeted, you have immuno checkpoints and you have cells. If you're putting the NK cell in combination with all this. So this is one complex achieve all of the combination. This is where all big pharma wants it and we luckily will have exclusive rights to the license from Mayo. They have close to 200 patent issued and application pending. So we're dominating on this space. This is the next generation.

    Mayank Mamtani

    Okay.

    Henry Ji

    People will be very excited.

    Mayank Mamtani

    So, maybe as you talk about your -- we didn't even get to oncolytic virus, but we'll save it for another time. Maybe can you just walk through some of the high value inflection points for 2021. And then also as y
    Bullish
  • A
    Ariadinvestor
    $SRNE conversation
    Added/Bought SRNE @ 6.906, 7.66 & 8.365 for son's Roth IRA on 4/12, 4/7 & 4/1. I don't sell but add more when it pulls back. I don't set stop loss. I don't buy on margin. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. I believe AUPH/SRNE will be my next ARIA. I always pick up gold bags whenever the price is right to me. Traders definitely won't agree with me. Please mute me. Long live $SRNE / $AUPH short squeeze !
    Bullish
  • W
    WildBill
    Ariad/I Strike is an obvious short. Filling the message board with drivel so there can be no discussion about the great news.
  • H
    Hound
    Short ariadpsycookooo giving positive messages 40+ thumbs down.
  • M
    M
    Ariadinvestor and IStrikeBack posts are being deleted from this board due to TOS violations..